Biosimilar and Biologics Market to Reach USD 1,257.3 Million by 2036 as Rising Biopharmaceutical Adoption and Biosimilar Approvals Accelerate Global Healthcare Growth

NEWARK, Del., July 24, 2026 - The Biosimilar and Biologics Market is expected to witness robust expansion as healthcare systems worldwide increasingly adopt cost-effective biologic therapies to improve patient access and reduce treatment costs. According to Future Market Insights (FMI), the market is projected to grow from USD 604.4 million in 2026 to USD 1,257.3 million by 2036, registering a 7.6% CAGR during the forecast period. Rising patent expirations of blockbuster biologics, increasing regulatory approvals for biosimilars, expanding biologics manufacturing capacity, and growing demand for targeted therapies are expected to drive sustained market growth over the next decade.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1250

The market is anticipated to generate an absolute dollar opportunity of USD 652.9 million between 2026 and 2036. Increasing investment in biopharmaceutical research, growing adoption of monoclonal antibodies, and expanding global manufacturing capabilities continue to strengthen demand for biosimilars and biologics.

Key Biosimilar and Biologics Market Highlights at a Glance

· Market Size (2026): USD 604.4 Million

· Forecast Market Size (2036): USD 1,257.3 Million

· Forecast Period: 2026-2036

· CAGR (2026-2036): 7.6%

· Absolute Dollar Opportunity: USD 652.9 Million

· Leading Drug Class: Monoclonal Antibodies (32.4% Market Share in 2026)

· Leading Source: Bacterial Cells (45.6% Market Share in 2026)

· Fastest-growing Country: China

· Key Countries: USA, Germany, France, UK

· Key Segments Covered: Drug Class, Source, Application, Manufacturing Type, Distribution Channel, Region

· Report Pages: 250

· Last Updated: July 15, 2026

· Reviewed by: Anurag Sharma

Why Is the Biosimilar and Biologics Market Growing?

The market continues to expand as pharmaceutical companies and healthcare providers increasingly embrace biosimilars and biologic therapies to improve treatment accessibility across oncology, autoimmune disorders, diabetes, inflammatory diseases, and rare diseases.

The expiration of patents for several blockbuster biologics, coupled with favorable regulatory pathways and growing healthcare cost-containment initiatives, is accelerating the adoption of biosimilar products worldwide.

Key Growth Drivers

· Increasing patent expirations of biologic drugs.

· Rising regulatory approvals for biosimilars.

· Growing demand for targeted biologic therapies.

· Expansion of biopharmaceutical manufacturing capacity.

· Rising prevalence of chronic and autoimmune diseases.

· Increasing healthcare expenditure worldwide.

· Growing focus on affordable treatment alternatives.

· Continuous investment in biologics research and development.

As healthcare systems seek to balance innovation with affordability, biosimilars are expected to play an increasingly important role in expanding patient access to advanced therapies.

👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-1250

According to Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights, "The biosimilar and biologics market is evolving through a combination of scientific innovation and healthcare affordability. Companies capable of delivering high-quality biologics while meeting stringent regulatory standards and ensuring reliable manufacturing capacity are expected to strengthen their competitive position as biosimilar adoption continues to expand globally."

Why Do Monoclonal Antibodies Lead the Biosimilar and Biologics Market?

Monoclonal Antibodies account for 32.4% of global market demand in 2026, making them the leading drug class.

These therapies have become a cornerstone of modern medicine due to their effectiveness in treating cancer, autoimmune diseases, inflammatory disorders, and other chronic conditions.

Drug Class Highlights

· Monoclonal antibodies dominate biologic therapies.

· Widely used across oncology and immunology.

· High clinical efficacy supports strong adoption.

· Expanding indications continue driving market demand.

Why Are Bacterial Cells the Leading Production Source?

Bacterial Cells account for 45.6% of market demand in 2026, supported by their efficiency in producing recombinant proteins and several therapeutic biologics.

Advancements in microbial fermentation technologies continue improving production scalability, manufacturing efficiency, and cost optimization for biopharmaceutical companies.

Source Highlights

· Bacterial cells dominate biologics manufacturing.

· Efficient recombinant protein production.

· Improved manufacturing scalability.

· Cost-effective commercial production capabilities.

👉 Explore the Latest Pharmaceutical Industry Analysis Now:
https://www.futuremarketinsights.com/industry-analysis/pharmaceuticals

How Are Biosimilars Transforming Healthcare?

Growing biosimilar adoption is improving patient access to life-saving biologic therapies by reducing treatment costs while maintaining comparable safety, efficacy, and quality to reference biologics.

Healthcare providers and payers are increasingly incorporating biosimilars into treatment protocols as reimbursement systems prioritize value-based care and healthcare affordability.

Market Trends

· Growing biosimilar approvals worldwide.

· Expansion of biologics manufacturing facilities.

· Increasing investment in next-generation biologics.

· Rising adoption of value-based healthcare models.

Market Dynamics

Market Drivers

Increasing prevalence of chronic diseases, growing demand for targeted therapies, rising regulatory approvals for biosimilars, expansion of biopharmaceutical manufacturing, increasing healthcare investments, and growing focus on affordable biologic treatments continue driving market growth.

Market Restraints

High manufacturing complexity, stringent regulatory requirements, significant research and development costs, patent litigation, supply chain challenges, and pricing competition continue presenting challenges for market participants.

Market Trends

Innovation continues reshaping the biosimilar and biologics landscape.

Major trends include:

· Expansion of monoclonal antibody pipelines.

· Increasing biosimilar approvals across major markets.

· Growth in contract biologics manufacturing.

· Rising investment in cell culture technologies.

· Greater focus on manufacturing automation.

· Strategic partnerships and licensing agreements.

Regional and Country Outlook

The United States remains a leading market, supported by advanced biologics research, favorable regulatory pathways, and strong demand for innovative therapies.

China is expected to be the fastest-growing market, driven by expanding biopharmaceutical manufacturing, increasing domestic biologics production, and significant government investment in biotechnology innovation.

Germany, France, Japan, Spain, and other major pharmaceutical markets continue expanding biosimilar adoption through supportive reimbursement policies and healthcare cost optimization initiatives.

Competitive Landscape

Competition remains centered on biologics innovation, biosimilar development, manufacturing excellence, regulatory approvals, and global commercialization capabilities.

Leading pharmaceutical companies continue investing in advanced biologics research, large-scale manufacturing infrastructure, and strategic collaborations to strengthen their product portfolios and global market presence.

Key Companies

· Pfizer

· Hoffmann-La Roche

· AbbVie

· Novartis

· Merck & Co.

· Amgen

· Biocon

· Intas Pharmaceuticals

· Viatris

· Serum Institute of India

👉 Read Full Report:
https://www.futuremarketinsights.com/reports/biosimilars-and-follow-on-biologics-market

Frequently Asked Questions

1. What is the projected size of the Biosimilar and Biologics Market by 2036?

The global Biosimilar and Biologics Market is projected to reach USD 1,257.3 million by 2036, growing from USD 604.4 million in 2026.

2. What is the expected CAGR of the Biosimilar and Biologics Market?

The market is forecast to expand at a 7.6% CAGR between 2026 and 2036.

3. Which drug class dominates the market?

Monoclonal Antibodies lead the market with a 32.4% share in 2026.

4. Which production source holds the largest market share?

Bacterial Cells dominate the market with a 45.6% share in 2026.

5. What factors are driving market growth?

Rising biosimilar approvals, increasing patent expirations of biologic drugs, growing demand for targeted therapies, expanding biopharmaceutical manufacturing, increasing prevalence of chronic diseases, and healthcare cost-containment initiatives are driving global market growth.

Related Reports

· https://sites.google.com/view/healthcarewellnessinsights/central-dialysis-fluid-delivery-system-cdds-market

· https://sites.google.com/view/healthcarewellnessinsights/pharmaceutical-drug-delivery-market

· https://sites.google.com/view/healthcarewellnessinsights/non-medical-grade-aesthetic-device-market

· https://sites.google.com/view/healthcarewellnessinsights/eclinical-solutions-and-software-market

· https://sites.google.com/view/healthcarewellnessinsights/radiopharmaceutical-market

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware 19713, USA
Rahul Singh
AVP - Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
For Media: Rahul.Singh@futuremarketinsights.com
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie® Award, and a member of the Greater New York Chamber of Commerce) provides deep insights into governing factors elevating demand in global markets.

FMI delivers market intelligence, consulting services, and syndicated research reports across chemicals, materials, food ingredients, pharmaceuticals, industrial manufacturing, sustainability, and advanced materials sectors.

With global expertise and industry-focused research capabilities, FMI provides actionable insights that help organizations understand market dynamics and identify emerging opportunities.

This release was published on openPR.